Pfizer’s FDA-Approved Adalimumab Faces Four-Year Wait

Abrilada May Launch From Late 2023 Under A Settlement With AbbVie

 
• By David Wallace
Pfizer
Pfizer has received an FDA nod for its Abrilada adalimumab biosimilar • Source: Shutterstock

More from Biosimilars

More from Products